ICER Review

Who decides which medications are available to Americans living with cancer? 

Increasingly, questions of access are informed by the Institute for Clinical and Economic Review, or ICER. ICER is a non-governmental health economics organization that uses clinical trials data and available pricing information to consider whether a drug is worth its cost. Though ICER lacks any formal authority, insurance companies often look to ICER reports to inform coverage policies. If ICER determines that a medication is not cost effective by their calculations, patients could be denied access.

Now, ICER is reviewing new treatments for chemotherapy-induced neutropenia, a severe side effect of chemotherapy that increases risk of infection and hospitalization. 

One of the two therapies under ICER review has not been FDA-approved, and has now been pulled back from the FDA approval process. Despite this, ICER is moving forward with its final report – without providing the cancer community the opportunity to voice their concerns at a public meeting, one of the few opportunities for patient input.

That’s why submitting public comment is so important. ICER needs to hear from stakeholders about our concerns before they prematurely finalize their report.

ICER Submission Guidelines 

It is very important you follow these guidelines so that your comments will be accepted.

  • Your letter must be submitted as a Word document (.doc) and sent via email as an attachment. PDFs are not accepted. ICER will not accept your letter if it is typed in the body of the email. 
  • Your letter cannot exceed 5 pages (not including references).
  • Your letter must be typed in Word, using Times New Roman font and 12-point font size.
  • In the subject line of your email please write: PUBLIC COMMENT: NOVEL AGENTS TO PREVENT CHEMOTHERAPY-INDUCED NEUTROPENIA AND OTHER MYELOSUPPRESSIVE EFFECTS
  • Your email with your letter attached as a Word document, should be sent to publiccomments@icer-review.org by February 22, 2022.

For questions or to get involved email Casey McPherson at CMcPherson@AllianceForPatientAccess.org.

Sample Social Media Posts

Get involved on social media by creating your own Tweet or posting one of the following:

  • ICER is reviewing new treatments for chemotherapy-induced neutropenia without providing the cancer community the opportunity to voice their concerns at a public meeting. Make sure they hear your voice. Get involved here: https://allianceforpatientaccess.org/icer/
  • ICER is reviewing new treatments for chemotherapy-induced neutropenia, a severe side effect of chemo. But the cancer community won’t have the opportunity to voice their concerns at their public meeting. Submit public comment and share your concerns: https://allianceforpatientaccess.org/icer/
  • New treatments for chemotherapy-induced neutropenia, a severe side effect of chemotherapy, could be life-changing for cancer patients. But does ICER see it that way? Get involved and submit public comment by February 22: https://allianceforpatientaccess.org/icer/
  • The ICER process is flawed, but as they are reviewing chemotherapy-induced neutropenia, they have cut out several important steps. With no public meeting, patients, providers and advocates must ensure their voices are still heard. Get involved here: https://allianceforpatientaccess.org/icer

Featured Resources

Patients Snubbed by Health Economists

Institute for Patient Access

The ICER Myth

Institute for Patient Access

The Institute for Clinical and Economic Review

Institute for Patient Access

Social Media Graphics

Institute for Patient Access

What’s Wrong With ICER?

Institute for Patient Access

Why Health Care Providers Should Care About ICER

Institute for Patient Access

Can ICER Fix What’s Broken?

Institute for Patient Access

What Patients Want from ICER

Institute for Patient Access

ICER Crosses the Center Line

Institute for Patient Access